Pharmacokinetic analysis of mizolastine in healthy young volunteers after single oral and intravenous doses: Noncompartmental approach and compartmental modeling

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 25, Issue 2, 1997, Pages 125-147

  Mesnil, Florence ^a   Dubruc, Catherine ^b   Mentre, France ^a   Huet, Sylvie ^c   Mallet, Alain ^a   Thenot, Jean Paul ^b  

^a INSERM   (France)

^b SANOFI   (France)

^c CEMAGREF   (France)

Author keywords

Bioavailability; Estimation; Heteroscedastic variance; Mizolastine; Noncompartmental approach; Nonlinear regression; Pharmacokinetic model; S PLUS library

Indexed keywords

ANTIHISTAMINIC AGENT; MIZOLASTINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MICROCAPSULE; MODEL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; TABLET;

EID: 0030670022     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025775912051     Document Type: Article

References (29)

1. 1 antihistamine. Ann. Allergy 69:135-139 (1992).
2. T. Hulot, G. Bianchetti, V. Ascalone, L. Flaminio, M. Picard, and P. L. Morselli. Absolute bioavailability and absorption kinetics of a new benzimidazole derivative, mizolastine, in healthy volunteers. Eur. J. Drug Metab. Pharmacokin. 18:36 (1993).
3. PHARM-NCA, Noncompartmental Pharmacokinetic Data Analysis Software, release 1.3e, SIMED SA, Créteil, France.
4. M. Rowland. Intra-individual variability in pharmacokinetics. In D. D. Breimer (ed.), Towards Better Safety of Drugs and Pharmaceutical Products, Elsevier/North-Holland, Amsterdam, The Netherlands, 1980.
5. C. Dubruc, P. Chrétien, G. Bianchetti, J. P. Thenot, and P. L. Morselli. Inter- and intra- subject variability of the pharmacokinetic profile of mizolastine in healthy young volunteers after a single 10 mg oral administration. Eur. J. Drug Metab. Pharmacokin. 18:118 (1993).
6. M. O. Karlsson and L. B. Sheiner. Estimating bioavailability when clearance varies with time. Clin. Pharmacol Ther. 55:623-637 (1994).
7. J. G. Wagner. Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, 1971.
8. A. Bouvier and S. Huet. NLS2. Nonlinear regression by S-PLUS functions. Comput. Stat. Data Anal. 18:187-190 (1994).
9. V. Ascalone, P. Guinebault, and A. Rouchouse. Determination of mizolastine, a new antihistaminic drug, in human plasma by liquid liquid extraction, solid-phase extraction and column-switching techniques in combination with high-performance liquid chromatography. J. Chromatog. 619:275-284 (1993).
10. J. G. Wagner. Fundamentals of Clinical Pharmacokinetics, Drug Intelligence Publications, Hamilton, 1975.
11. M. Gibaldi and D. Perrier. Pharmacokinetics, Marcel Dekker, New York, 1982.
12. S-PLUS User's Manual, Statistical Sciences, Seattle, 1991.
13. S. Huet, A Bouvier, M. A. Gruet, and E. Jolivet. Statistical Tools for Nonlinear Regression: A Practical Guide with S-PLUS Examples. Springer-Verlag, Berlin, 1996.
14. H. Akaike. A new look at the statistical model identification. IEEE Trans. Automat. Contr. 19:716-723 (1974).
15. T. L. Ludden, S. L. Beal, and L. B. Sheiner. Comparison of the Akaike Information Criterion, the Schwartz criterion, and the F test as guides to model selection. J. Pharmacokin. Biopharm. 22:431-436 (1994).
16. J. D. Gibbons. Nonparametric Statistical Inference, McGraw-Hill, New York, 1971.
17. S. Holm. A simple sequentially rejective multiple test procedure. Scand. J. Statist. 6: 65- 70 (1979).
18. W. R. Gillespie. Noncompartmental versus compartmental modeling in clinical pharmacokinetics. Clin. Pharmacokin. 20:253-262 (1991).
19. K. E. Fattinger and D. Verotta. Estimating bioavailability when clearance changes in time: The effect of model misspecification. Clin. Pharmacol. Ther. 58:595-600 (1995).
20. M. O. Karlsson and U. Bredberg. Estimation of bioavailability on a single occasion after semisimultaneous drug administration. Pharm. Res. 6:817-821 (1989).
21. P. S. Collier and S. Riegelman. Estimation of absolute bioavailability assuming steady state apparent volume of distribution remains constant. J. Pharmacokin. Biopharm. 11:205- 214 (1983).
22. Y. Kasuya, T. Suruta, H. Shibasaki, and H. Shimota. Evaluation of the utility of a proposed method for correcting for intrasubject variability in metabolic clearance in the bioavailability assessment of the theophylline. J. Pharmacokin. Biopharm. 19:113-116 (1991).
23. S. D. Hall, C. B. McAllister, and G. R. Wilkinson. The assessment of bioavailability in the presence of nonlinear elimination. J. Pharmacokin. Biopharm. 16:263-278 (1988).
24. M. O. Karlsson and U. Bredberg. Bioavailability estimation by semisimultaneous drug administration: A Monte Carlo simulation study. J. Pharmacokin. Biopharm. 18:103-120 (1990).
25. M. Davidian and D. M. Giltinan. Nonlinear Models for Repeated Measurement Data, Chapman and Hall, London, 1995.
26. R. J. Carroll and D. Ruppert. A comparison between Maximum Likelihood and Generalized Least Squares, in a heteroscedastic linear model. J. Am. Statist. Assoc. 77:878- 882 (1982).
27. L. B. Sheiner and S. L. Beal. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J. Pharmacokin. Biopharm. 13: 185-201 (1985).
28. D. M. Giltinan and D. Ruppert. Fitting heteroscedastic regression models to individual pharmacokinetic data using standard statistical software. J. Pharmacokin. Biopharm. 17:601-614 (1989).
29. A. Messéan. A generalization of Gauss-Marquardt algorithm for exponential families problems. Comput. Statist. Quart. 4:79-88 (1988).